Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors

John M. Kirkwood, Ahmad Tarhini, Joseph A. Sparano, Prapti Patel, Joan H. Schiller, Maxwell T. Vergo, Al B. Benson, Hussein Tawbi

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Adjuvant therapy employing cytotoxic chemotherapy, molecularly targeted agents, immunologic, and hormonal agents has shown a significant impact upon a variety of solid tumors. The principles that guide adjuvant therapy differ among various tumor types and specific modalities, but generally indicate a greater impact of therapy in the postsurgical setting of micrometastatic disease, for which adjuvant therapy is commonly pursued, vs. the setting of gross unresectable disease. This review of adjuvant therapies in current use for five major solid tumors highlights the rationale for current effective adjuvant therapy, and draws comparisons between the adjuvant regimens that have found application in solid tumors.

Original languageEnglish (US)
Pages (from-to)27-43
Number of pages17
JournalCancer Treatment Reviews
Volume39
Issue number1
DOIs
StatePublished - Feb 1 2013

Keywords

  • Adjuvant
  • Chemotherapy
  • Disease-free survival
  • Immunotherapy
  • Molecularly targeted therapy
  • Neoplasms
  • Progression-free survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors'. Together they form a unique fingerprint.

  • Cite this

    Kirkwood, J. M., Tarhini, A., Sparano, J. A., Patel, P., Schiller, J. H., Vergo, M. T., Benson, A. B., & Tawbi, H. (2013). Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. Cancer Treatment Reviews, 39(1), 27-43. https://doi.org/10.1016/j.ctrv.2012.03.007